Advanced Therapies 2021 brings together the life science community to meet, do business and solve the challenges preventing ATMPs getting to market and saving patient lives.

The event covers each stage of development of cell, gene and immunotherapy - from bioprocessing through clinical translation to reimbursement, market access and delivery to patient.

TOPICS: Track 1: Commercialisation

  • Deals, mergers and acquisitions: what have we learnt and where are we going in 2022?
  • The rise of allogeneic cells
  • Evidence, pricing & market access
  • Investment, commercialisation and BD
  • What we learned about logistics and transportation during COVID
  • Regulatory session for academic and early-stage companies
  • Tackling large-scale, commercial regulatory challenges
     

TOPICS: Track 2: Latest developments

  • What have we learned from COVID and how is the industry moving forward? 
  • Remote trials became a reality in 2020, what next?
  • How prevent deaths and ensure future clinical success
  • Tackling solid tumours
  • Next generation of gene therapy 
  • Immunogenicity for gene therapy
  • Cord blood advancements
  • MSCs vs iPSCs for major disease
  • Novel next generation gene editing
  • Rare disease & orphan drugs

TOPICS: Track 3: Manufacture & bioprocess

  • How can advances in COVID vaccine manufacture help us move forward?
  • How POC patient delivery needs to develop in the next 5 years
  • Cell therapy manufacturing
  • Closed systems and automated manufacture.
  • Scaling up manufacture to a commercial level
  • Effective process development and keeping costs low
  • Viral vector analytics and safe manufacture

     

Stay up to date